This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
erk1-2
ERK1/2
Terminal kinases of the RAS-RAF-MEK-ERK cascade; activated by RTKs, BRAF, and KRAS → RSK, ELK1, c-FOS → proliferation and survival. BRAF V600E and KRAS mutations drive constitutive ERK activation; MEK inhibitors (trametinib, cobimetinib) block ERK in BRAF-mutant tumors.
Entry Metadata
| Field | Value |
|---|---|
| ID | erk1-2 |
| Name | ERK1/2 |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol. 1997;9(2):180-186. · PubMed 9069255
- Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875-885. · PubMed 15520807
- Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451. · PubMed 26037941